What’s Driving NASH?
  • CME
  • CE

The pathogenesis of NASH is complex, but there’s insight in looking at diabetes, obesity, and insulin resistance through the lens of the liver.
Brent A. Neuschwander-Tetri, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: January 29, 2021 Expiration: January 28, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explain the common underlying causes of obesity, diabetes, and NASH
  • Apply best practices in the lifestyle and pharmacologic management of NASH

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Associate Chair for Clinical Trials
Saint Louis University School of Medicine
St Louis, Missouri

Brent A. Neuschwander-Tetri, MD, has disclosed that he has received consulting fees from 89Bio, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus, Cymabay, Enanta, Fortress, Genfit, Gilead Sciences, High Tide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, MedImmune, Merck, Mirum, NGM, Novo Nordisk, Novus Therapeutics, pH Pharma, Sagimet, and Target RWE; has received funds for research support from Allergan, Bristol-Myers Squibb, Cirius, Enanta, Genfit, Gilead Sciences, Intercept, Madrigal, and NGM; and has ownership interest in HepGene.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The online activities are intended for hepatologists, gastroenterologists, endocrinologists, and other physicians, nurses, pharmacists, and healthcare providers who manage individuals with or who are at risk for NASH.

Goal

The goal of this comprehensive program is to arm learners with foundational education in NASH pathogenesis, diagnosis, current recommended management, and emerging pharmacologic treatment strategies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-026-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 29, 2021, through January 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Unlocked slides from Wing-Kin Syn, MBChB, PhD, FACP, FRCP and CCO: How to use biomarkers and imaging to evaluate NAFLD and NASH—ruling in or out hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Released: April 27, 2021

Video from CCO: best practice for identifying NAFLD and risk of progression to NASH. Biomarkers and imaging to rule in or out significant/advanced hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 27, 2021 Expired: April 26, 2022

Expert commentary discussing noninvasive testing for patients with diabetes who are at risk for NAFLD/NASH, from Clinical Care Options (CCO)

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: April 19, 2022

Expert commentary discussing the early identification and prognosis of NAFLD, from Clinical Care Options (CCO)

Manal F. Abdelmalek, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 16, 2021 Expired: March 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue